Hologic (NASDAQ:HOLX) Price Target Increased to $82.00 by Analysts at Evercore ISI

Hologic (NASDAQ:HOLX) had its target price hoisted by analysts at Evercore ISI from $78.00 to $82.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “in-line” rating on the medical equipment provider’s stock. Evercore ISI’s target price indicates a potential upside of 2.80% from the company’s current price.

HOLX has been the subject of several other reports. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $95.00 to $85.00 in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, September 17th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $79.77 on Tuesday. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The company has a 50-day moving average price of $81.22 and a 200-day moving average price of $77.38. The company has a market cap of $18.62 billion, a price-to-earnings ratio of 40.70, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic has a 12 month low of $64.02 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the business posted $0.93 EPS. The business’s revenue was up 2.7% on a year-over-year basis. As a group, equities analysts anticipate that Hologic will post 4.09 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 over the last ninety days. Insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. Innealta Capital LLC bought a new stake in shares of Hologic during the 2nd quarter valued at $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic during the 1st quarter valued at about $37,000. Sunbelt Securities Inc. bought a new position in shares of Hologic during the 2nd quarter valued at approximately $37,000. Cranbrook Wealth Management LLC bought a new stake in Hologic during the 2nd quarter worth approximately $47,000. Finally, Mather Group LLC. purchased a new position in Hologic during the first quarter valued at approximately $48,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.